Merck & Company Inc (MRK)vsPACS Group, Inc. (PACS)
MRK
Merck & Company Inc
$119.60
+0.88%
HEALTHCARE · Cap: $283.78B
PACS
PACS Group, Inc.
$37.77
-1.23%
HEALTHCARE · Cap: $5.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1111% more annual revenue ($65.77B vs $5.43B). MRK leads profitability with a 13.6% profit margin vs 4.5%. PACS appears more attractively valued with a PEG of 1.07. PACS earns a higher WallStSmart Score of 60/100 (C+).
MRK
Hold50
out of 100
Grade: D+
PACS
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$119.60
$38.64 premium
Intrinsic value data unavailable for PACS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 194.1% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
4.5% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. Revenue growth of 11.2% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PACS
The primary concerns for PACS are Profit Margin, Altman Z-Score, Debt/Equity. Debt-to-equity of 3.38 is elevated, increasing financial risk. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
PACS is growing revenue faster at 11.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PACS scores higher overall (60/100 vs 50/100) and 11.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a leading technology solutions provider focused on enhancing operational efficiency through a suite of innovative software and hardware systems tailored for diverse industries. The company places a strong emphasis on research and development, positioning itself to capitalize on emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic partnerships and a solid market presence, PACS Group is strategically poised to sustain and enhance its competitive advantage, presenting a compelling investment opportunity for institutional investors looking to tap into growth within the dynamic technology sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?